Fujirebio Europe launches the automated Lumipulse® G SCC assay for the quantitative measurement of squamous cell carcinoma antigen

Fujirebio Europe announces the release of the Lumipulse G SCC assay for the automated quantitative measurement of squamous cell carcinoma (SCC) antigen in human serum or plasma.

Fujirebio Europe announces the release of the Lumipulse G SCC assay for the automated quantitative measurement of squamous cell carcinoma (SCC) antigen in human serum or plasma. The Lumipulse G SCC is based on a two-step sandwich immunoassay method for the LUMIPULSE G System and uses fully automated unique cartridge CLEIA technology.

More information

Details

Technologiepark-Zwijnaarde 6, 9052 Gent, Belgium

Christian Lindknud

Keywords

Immunoassay test kits

Associated Trend items

Fujirebio expands its Alzheimer’s disease test menu with the much awaited and fully automated Lumipulse® G pTau 217 Plasma assay for Research Use Only (RUO)

This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma within just 35 minutes.

Gent, Belgium, Malvern PA, United States, and Tokyo, Japan, December 22nd, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measuremen...

More information

Fujirebio Europe expands its portfolio with introduction of the innovative PreCursor-M AnoGYN assay (RUO) for methylation testing in anal specimens

The test is intended for the detection of promoter hypermethylation of the genes ASCL1 and ZNF582 and is used to test the methylations status of anal specimens for research use only (RUO)

Gent, Belgium and Amsterdam, The Netherlands – March 5th, 2024: Fujirebio Europe and Self-screen B.V. today announced an expansion of their commercial collaboration with the distribution of the PreCursor-M AnoGYN methylation-specific molecular assay from Self-screen B.V. The test is intended for the detection of promoter hypermethylation of the genes ASCL1 and ZNF582 an...

More information

Fujirebio and Agappe enter into an agreement on business collaboration in the field of CLIA based immunoassay

This collaboration is driven by a mutual belief that leveraging their distinct strengths will not only spur the expansion of India's immunoassay market but also significantly impact the evolution and enhancement of immunoassay solutions in India.

Tokyo, Japan and Cochin, India, January 19, 2024, Friday --- Fujirebio Holdings, Inc. and Agappe Diagnostics Ltd today announced that they have entered into an agreement of Contract Development and Manufacturing Organization (CDMO) partnership for Cartridge based CLIA system reagents manufacturing project for the immunology equipment Mispa i60 and Mispa i121. Notably, th...

More information

Compare

Remove all

Compare up to 10 products